Evidence map›Paper›PMID 35228422›Full record

ArticleInternal medicine (Tokyo, Japan)2022

A Propensity Score Matched Analysis of Statin Effects on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients Over 75 Years Old.

Takeo Horikoshi, Takamitsu Nakamura, Toru Yoshizaki, Jun Nakamura, Yosuke Watanabe, Manabu Uematsu, Aritaka Makino, Yukio Saito, Jun-Ei Obata, Takao Sawanobori and 6 more

Open access · diamondAbstract readMulticenter Study
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Takeo HorikoshiDepartment of Internal Medicine II, Faculty of Medicine, University of Yamanashi, Japan.
Takamitsu NakamuraDepartment of Internal Medicine II, Faculty of Medicine, University of Yamanashi, Japan.
Toru YoshizakiDepartment of Internal Medicine II, Faculty of Medicine, University of Yamanashi, Japan.
Jun NakamuraDepartment of Cardiology, Fujieda Municipal General Hospital, Japan.
Yosuke WatanabeDepartment of Internal Medicine II, Faculty of Medicine, University of Yamanashi, Japan.
Manabu UematsuDepartment of Internal Medicine II, Faculty of Medicine, University of Yamanashi, Japan.
Aritaka MakinoDepartment of Internal Medicine, Yamanashi Prefectural Central Hospital, Japan.
Yukio SaitoDepartment of Cardiology, Kofu Municipal Hospital, Japan.
Jun-Ei ObataDepartment of Internal Medicine II, Faculty of Medicine, University of Yamanashi, Japan.
Takao SawanoboriDepartment of Cardiology, Kofu Municipal Hospital, Japan.
Hajime TakanoDepartment of Cardiology, Kofu Jonan Hospital, Japan.
Ken UmetaniDepartment of Internal Medicine, Yamanashi Prefectural Central Hospital, Japan.
Akinori WatanabeDepartment of Cardiology, Fujieda Municipal General Hospital, Japan.
Tetsuya AsakawaDepartment of Cardiology, Yamanashi Kosei Hospital, Japan.
Akira SatoDepartment of Internal Medicine II, Faculty of Medicine, University of Yamanashi, Japan.
Kiyotaka KugiyamaDepartment of Internal Medicine II, Faculty of Medicine, University of Yamanashi, Japan.
University of Yamanashi · JPFujieda Municipal General Hospital · JPGifu Municipal Hospital · JPYamanashi Prefectural Central Hospital · JPUniversity of Yamanashi Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective In an extremely aging society, it is beneficial to reconsider the value of medical treatment for extremely elderly patients. We therefore focused on the efficacy of statin therapy in extremely elderly patients. This study investigated the efficacy of statins for secondary prevention in patients over 75 years old. Methods This prospective multicenter registry included 1,676 consecutive extremely elderly patients with coronary artery disease who underwent successful percutaneous coronary intervention (PCI). The patients were followed up clinically for up to three years or until the occurrence of major adverse cardiac events (MACEs), defined as a composite of all-cause death and non-fatal myocardial infarction. Using propensity score methodology to eliminate selection bias, in a 1:1 matching ratio, we selected 466 pairs of patients for the analysis. Results During the median follow-up period of 25 months, MACEs occurred in 176 patients. The Kaplan-Meier analysis showed that statin treatment correlated with a lower probability of initial MACE occurrences within 30 days compared with no statin treatment (log-rank test, p<0.001). According to a landmark analysis at day 30, statin treatment still showed consistent effectiveness for reducing MACE occurrence during the follow up period (p=0.04). A multivariable Cox hazard analysis showed that statin therapy significantly reduced MACE occurrence (hazard ratio 0.55 [0.40-0.75], p<0.001). In the stratification analysis, statin therapy was especially beneficial in patients without symptomatic heart failure. Conclusion Statins were effective in preventing MACEs in extremely elderly patients after PCI.

Indexed as

Coronary Artery DiseaseHydroxymethylglutaryl-CoA Reductase InhibitorsMyocardial InfarctionPercutaneous Coronary InterventionAgedAged, 80 and overHumansPropensity ScoreProspective StudiesRisk FactorsTreatment OutcomeHydroxymethylglutaryl-CoA Reductase Inhibitorsagingcardiovascular diseasesmortalitypercutaneous coronary interventionstatin

Identifiers

PMID35228422
PMCPMC9556242
OpenAlexW4214662084

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.